Abstract:T-cells genetically engineered to express a chimeric antigen receptor (CAR) have shown remarkable results in patients with B-cell malignancies, including B-cell acute lymphoblastic leukemia, diffuse large B-cell lymphoma, and mantle cell lymphoma, with some promising efficacy in patients with multiple myeloma. However, the efficacy of CAR T-cell therapy is still hampered by local immunosuppression and significant toxicities, notably cytokine release syndrome (CRS) and neurotoxicity. The tumor microenvironment (TME) has been identified to play a major role in preventing durable responses to immunotherapy in both solid and hematologic malignancies, with this role exaggerated in solid tumors. The TME comprises a diverse set of components, including a heterogeneous population of various cells and acellular elements that collectively contribute towards the interplay of pro-immune and immunosuppressive signaling. In particular, macrophages, myeloid-derived suppressor cells, regulatory T-cells, and cell-free factors such as cytokines are major contributors to local immunosuppression in the TME of patients treated with CAR T-cells. In order to create a more favorable niche for CAR T-cell function, armored CAR T-cells and other combinatorial approaches are being explored for potential improved outcomes compared to conventional CAR T-cell products. While these strategies may potentiate CAR T-cell function and efficacy, they may paradoxically increase the risk of adverse events due to increased pro-inflammatory signaling. Herein, we discuss the mechanisms by which the TME antagonizes CAR T-cells and how innovative immunotherapy strategies are being developed to address this roadblock. Furthermore, we offer perspective on how these novel approaches may affect the risk of adverse events, in order to identify ways to overcome these barriers and expand the clinical benefits of this treatment modality in patients with diverse cancers. Precise immunomodulation to allow for improved tumor control while simultaneously mitigating the toxicities seen with current generation CAR T-cells is integral for the future application of more effective CAR T-cells against other malignancies.

Novel Strategies to Improve CAR-T Cell Efficacy by Targeting the Solid Tumor Microenvironment

Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment

Targeting the Immune-Suppressive Tumor Microenvironment to Potentiate CAR T Cell Therapy

Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies

Innovative Strategies to Advance CAR T Cell Therapy for Solid Tumors.

Current Challenges and Strategies for Chimeric Antigen Receptor-T-Cell Therapy for Solid Tumors

Advanced Strategies of CAR-T Cell Therapy in Solid Tumors and Hematological Malignancies

Rationally designed approaches to augment CAR-T therapy for solid tumor treatment

Modulating Tumor Physical Microenvironment for Fueling CAR-T Cell Therapy.

Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies

Extant challenges and optimization strategies for CAR-T cell therapy for solid tumors

CAR-T in solid tumors: Blazing a new trail through the brambles

Elevating the potential of CAR-T cell therapy in solid tumors: exploiting biomaterials-based delivery techniques

Hurdles of CAR-T Cell-Based Cancer Immunotherapy Directed Against Solid Tumors.

Chimeric Antigen Receptor T Cells Applied to Solid Tumors

Delivery Techniques for Enhancing CAR T Cell Therapy Against Solid Tumors

Befriending the Hostile Tumor Microenvironment in CAR T-Cell Therapy

CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment

Breaking the shield of solid tumors: a combined approach for enhanced efficacy of CAR-T cells

Chimeric Antigen Receptor-T Cell Therapy for Solid Tumors Require New Clinical Regimens

Reshaping the tumor immune microenvironment to improve CAR-T cell-based cancer immunotherapy